|53.87||+3.57||+7.10%||Vol 2.42M||1Y Perf 0.74%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||72.46||Analyst Rating||Moderate Buy 1.60|
|Potential %||34.51||Finscreener Ranking||★+ 43.04|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 41.21|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★ 43.81|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||45.44||Earnings Rating||Strong Buy|
|Market Cap||6.38B||Earnings Date||1st Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.86|
|EPS Growth Next 5 Years %||38.30|
|Avg. Weekly Volume||1.48M|
|Avg. Monthly Volume||1.80M|
|Avg. Quarterly Volume||2.24M|
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) stock closed at 53.87 per share at the end of the most recent trading day (a 7.1% change compared to the prior day closing price) with a volume of 2.42M shares and market capitalization of 6.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 374 people. Apellis Pharmaceuticals Inc. CEO is Cedric Francois.
The one-year performance of Apellis Pharmaceuticals Inc. stock is 0.74%, while year-to-date (YTD) performance is 4.18%. APLS stock has a five-year performance of 251.17%. Its 52-week range is between 19.8301 and 94.75, which gives APLS stock a 52-week price range ratio of 45.44%
Apellis Pharmaceuticals Inc. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 16.76, a price-to-sale (PS) ratio of 99.93, a price to cashflow ratio of -, a PEG ratio of -0.20, a ROA of -96.21%, a ROC of -215.54% and a ROE of -489.94%. The company’s profit margin is -89.24%, its EBITDA margin is -532.80%, and its revenue ttm is $52.76 Million , which makes it $0.48 revenue per share.
Of the last four earnings reports from Apellis Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. Apellis Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Apellis Pharmaceuticals Inc. is Moderate Buy (1.6), with a target price of $72.46, which is +34.51% compared to the current price. The earnings rating for Apellis Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apellis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apellis Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.51, ATR14 : 2.70, CCI20 : 260.89, Chaikin Money Flow : 0.23, MACD : 1.18, Money Flow Index : 66.14, ROC : 14.64, RSI : 66.72, STOCH (14,3) : 89.78, STOCH RSI : 1.00, UO : 61.52, Williams %R : -10.22), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apellis Pharmaceuticals Inc. in the last 12-months were: A. Sinclair Dunlop (Sold 2 000 shares of value $113 645 ), Adam J. Townsend (Option Excercise at a value of $226 350), Adam J. Townsend (Sold 25 000 shares of value $1 474 100 ), Alec Machiels (Option Excercise at a value of $16 688), Alec Machiels (Sold 6 250 shares of value $377 788 ), Cedric Francois (Option Excercise at a value of $3 635 881), Cedric Francois (Sold 361 400 shares of value $20 698 368 ), Chopas James (Sold 683 shares of value $28 795 ), Dunlop A. (Sold 34 894 shares of value $1 741 956 ), Federico Grossi (Sold 5 000 shares of value $246 800 ), Grossi Federico (Sold 2 500 shares of value $121 975 ), Jeffrey Eisele (Sold 14 016 shares of value $781 586 ), Karen Lewis (Sold 0 shares of value $-341 100 ), Karen Lewis (Sold 14 942 shares of value $1 079 917 ), Machiels Alec (Option Excercise at a value of $13 350), Machiels Alec (Option Exercise at a value of $133 500), Machiels Alec (Sold 5 000 shares of value $233 225 ), Mark Jeffrey Delong (Sold 131 shares of value $6 031 ), Nicholson Nur (Sold 0 shares of value $-289 237 ), Nicholson Nur (Sold 20 350 shares of value $900 860 ), Pascal Deschatelets (Option Excercise at a value of $735 549), Pascal Deschatelets (Sold 132 000 shares of value $7 535 400 ), Scheibler Lukas (Sold 1 756 shares of value $75 526 ), Sullivan Timothy Eugene (Option Exercise at a value of $699 883), Sullivan Timothy Eugene (Sold 69 779 shares of value $6 196 527 ), Timothy Eugene Sullivan (Sold 0 shares of value $-699 883 ), Timothy Eugene Sullivan (Sold 69 779 shares of value $6 196 653 ), Townsend Adam (Sold 0 shares of value $-377 250 ), Townsend Adam (Sold 25 000 shares of value $1 635 750 )
Mon, 25 Sep 2023 10:01 GMT Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and DENTSPLY SIRONA (XRAY)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.